Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. doi: 10.1073/pnas.0908201106. Epub 2009 Sep 2.

2.

Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach.

Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C.

Biochemistry. 2011 Mar 15;50(10):1755-62. doi: 10.1021/bi101662j. Epub 2011 Feb 14.

3.

Transtumoral targeting enabled by a novel neuropilin-binding peptide.

Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E.

Oncogene. 2012 Aug 16;31(33):3754-63. doi: 10.1038/onc.2011.537. Epub 2011 Dec 19.

PMID:
22179825
4.

Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor.

Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Alemán C, Haspel N.

J Struct Biol. 2013 May;182(2):78-86. doi: 10.1016/j.jsb.2013.02.006. Epub 2013 Feb 24.

PMID:
23462097
5.

Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.

Kamarulzaman EE, Vanderesse R, Gazzali AM, Barberi-Heyob M, Boura C, Frochot C, Shawkataly O, Aubry A, Wahab HA.

J Biomol Struct Dyn. 2017 Jan;35(1):26-45. doi: 10.1080/07391102.2015.1131196. Epub 2016 May 23.

PMID:
26766582
6.

Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition.

Parker MW, Xu P, Guo HF, Vander Kooi CW.

PLoS One. 2012;7(11):e49177. doi: 10.1371/journal.pone.0049177. Epub 2012 Nov 8.

7.

Tumor-penetrating peptides.

Teesalu T, Sugahara KN, Ruoslahti E.

Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013.

8.

An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.

Pang HB, Braun GB, Friman T, Aza-Blanc P, Ruidiaz ME, Sugahara KN, Teesalu T, Ruoslahti E.

Nat Commun. 2014 Oct 3;5:4904. doi: 10.1038/ncomms5904.

9.

Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.

Paoli EE, Ingham ES, Zhang H, Mahakian LM, Fite BZ, Gagnon MK, Tam S, Kheirolomoom A, Cardiff RD, Ferrara KW.

J Control Release. 2014 Mar 28;178:108-17. doi: 10.1016/j.jconrel.2014.01.005. Epub 2014 Jan 13.

10.

SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide.

Feng GK, Liu RB, Zhang MQ, Ye XX, Zhong Q, Xia YF, Li MZ, Wang J, Song EW, Zhang X, Wu ZZ, Zeng MS.

J Control Release. 2014 Oct 28;192:236-42. doi: 10.1016/j.jconrel.2014.07.039. Epub 2014 Jul 22.

PMID:
25058570
11.

Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.

PMID:
16959272
12.

Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1.

Parker MW, Linkugel AD, Vander Kooi CW.

J Mol Biol. 2013 Nov 15;425(22):4405-14. doi: 10.1016/j.jmb.2013.07.017. Epub 2013 Jul 17.

13.

Mechanistic basis for the potent anti-angiogenic activity of semaphorin 3F.

Guo HF, Li X, Parker MW, Waltenberger J, Becker PM, Vander Kooi CW.

Biochemistry. 2013 Oct 29;52(43):7551-8. doi: 10.1021/bi401034q. Epub 2013 Oct 18.

14.

The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.

Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W.

Cancer Res. 2007 Oct 15;67(20):9623-9.

15.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

16.

Neuropilin-1 regulates a new VEGF-induced gene, Phactr-1, which controls tubulogenesis and modulates lamellipodial dynamics in human endothelial cells.

Allain B, Jarray R, Borriello L, Leforban B, Dufour S, Liu WQ, Pamonsinlapatham P, Bianco S, Larghero J, Hadj-Slimane R, Garbay C, Raynaud F, Lepelletier Y.

Cell Signal. 2012 Jan;24(1):214-23. doi: 10.1016/j.cellsig.2011.09.003. Epub 2011 Sep 10.

PMID:
21939755
17.

Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1.

Novoa A, Pellegrini-Moïse N, Bechet D, Barberi-Heyob M, Chapleur Y.

Bioorg Med Chem. 2010 May 1;18(9):3285-98. doi: 10.1016/j.bmc.2010.03.012. Epub 2010 Mar 12.

PMID:
20363638
18.

Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex.

Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, Navaza A, du Penhoat CH, Perret GY.

Peptides. 2007 Dec;28(12):2397-402. Epub 2007 Sep 29.

PMID:
17983687
19.

Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR.

Cébe-Suarez S, Grünewald FS, Jaussi R, Li X, Claesson-Welsh L, Spillmann D, Mercer AA, Prota AE, Ballmer-Hofer K.

FASEB J. 2008 Aug;22(8):3078-86. doi: 10.1096/fj.08-107219. Epub 2008 May 8.

PMID:
18467594
20.

Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.

Kim YJ, Bae J, Shin TH, Kang SH, Jeong M, Han Y, Park JH, Kim SK, Kim YS.

J Control Release. 2015 Oct 28;216:56-68. doi: 10.1016/j.jconrel.2015.08.016. Epub 2015 Aug 8.

PMID:
26260451

Supplemental Content

Support Center